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Abstract
The molecular interaction between adenosine A2A and dopamine D2 receptors (A2ARs and D2Rs,
respectively) within an oligomeric complex has been postulated to play a pivotal role in the
adenosine-dopamine interplay in the central nervous system, in both normal and pathological
conditions (e.g. Parkinson’s disease). While the effects of A2AR challenge on D2R functioning
have been largely studied, the reverse condition is still unexplored, a fact that might have impact
in therapeutics. Here, we aimed to examine in a real-time mode the D2R-mediated allosteric
modulation of A2AR binding when an A2AR/D2R oligomer is established. Thus, we synthesized
fluorescent A2AR agonists and evaluated, by means of a flow cytometry homogeneous no-wash
assay and a real-time fluorescence resonance energy transfer (FRET)-based approach, the effects
on A2AR binding of distinct antiparkinsonian drugs in current clinical use (i.e. pramipexole,
rotigotine and apomorphine). Our results provided evidence for the existence of a differential
D2R-mediated negative allosteric modulation on A2AR agonist binding that was oligomer-
formation dependent, and with apomorphine being the best antiparkinsonian drug attenuating
A2AR agonist binding. Overall, the here-developed methods were found valid to prospect the
ability of drugs acting on D2Rs to modulate A2AR binding, thus featuring as possible helpful tools
for the preliminary selection of D2R-like candidate drugs in the management of Parkinson’s
disease.
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1. Introduction
Parkinson’s disease (PD) is a progressive systemic neurodegenerative disorder associated
with, but not exclusively, the loss of pigmented dopaminergic neurons located at the
substantia nigra pars compacta (Lang and Lozano, 1998). Interestingly, the control of this
circuitry both in normal and pathological conditions is not only mediated by dopamine
receptors, but also by other G protein-coupled receptors (GPCRs), for instance adenosine
receptors, which may functionally and molecularly interact with the dopaminergic system
(Ferre et al., 2004). Indeed, an interaction between adenosine A2A and dopamine D2
receptors (A2ARs and D2Rs, respectively) has been demonstrated in heterologous expression
systems and there is accumulated evidence for the coexistence of reciprocal antagonistic
interactions between A2ARs and D2Rs in the same neurons, the GABAergic enkephalinergic
neurons (Ferre et al., 2008). Thus, since drugs acting on A2ARs would modulate
dopaminergic neurotransmission they have been proposed as therapeutic tools in PD, and in
fact, A2AR antagonists have been recently introduced in the symptomatic treatment of the
former pathology (for review see (Xu et al., 2005,Morelli et al., 2009,Schwarzschild et al.,
2006)). Hence, it has been suggested that the modulation of a feasible A2AR/D2R complex
by means of simultaneous D2R activation and A2AR inhibition would represent a valuable
target for PD pharmacotherapy. Accordingly, in the present work we aimed to analyze the
reciprocal A2AR-D2R antagonistic interaction, concretely the possible D2R-mediated
allosteric modulation of A2AR agonist binding. Thus, by means of a real-time fluorescence
resonance energy transfer (FRET)- and a flow cytometry-assays, we evaluated the effects of
different antiparkinsonian drugs (i.e. pramipexole, rotigotine and apomorphine), in order to
provide further information regarding D2R-based drugs before being selected for PD
treatment.
2. Materials and Methods
2.1. Materials
The primary antibodies used were: rabbit anti-A2AR polyclonal antibody (Ciruela et al.,
2004), rabbit anti-D2R polyclonal antibody (Millipore, Temecula, CA, USA), and mouse
anti-A2AR monoclonal antibody (clone 7F6-G5-A2; Millipore). The secondary antibodies
were: horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Pierce Biotechnology,
Rockford, IL, USA) and Cy3-conjugated donkey anti-mouse IgG antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA). The ligands used were: adenosine,
pramipexole, apomorphine from Sigma-Aldrich (St. Louis, MO, USA); CGS21680,
ZM241,385, rotigotine from Tocris Bioscience (Ellisville, MI, USA). Adenosine deaminase
was purchased from Roche Diagnostics (GmbH, Mannheim, Germany) and zardaverine
from Calbiochem (San Diego, CA, USA).
2.2. Synthesis of the A2AR fluorescent agonists
The APECAlexa488 (MRS5206) and the APECAlexa532 (MRS5424) are functional agonists at
the adenosine A2AR, in which the fluorescent dyes Alexa488 and 532, respectively, are
covalently attached to the A2AR agonist 2-[[2-[4-[2-(2-aminoethyl)-aminocarbonyl]
ethyl]phenyl]ethylamino]-5′-N-ethyl-carboxamidoadenosine (APEC). MRS5424, and
similarly MRS5206, were synthesized as previously described (Fernandez-Duenas et al.,
2012).
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To perform FRET experiments with the MRS5424 fluorescent agonist, a CFP-tagged A2AR
(A2ARCFP) and an AGT-tagged D2R (D2RAGT) were cloned, as previously described
(Fernandez-Duenas et al., 2012).
2.4. Cell culture, transfection and membrane preparation
Human embryonic kidney (HEK)-293 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Sigma-Aldrich) supplemented with 1 mM sodium pyruvate, 2 mM L-
glutamine, 100 U/mL streptomycin, 100 mg/mL penicillin and 5% (v / v) fetal bovine serum
at 37° C and in an atmosphere of 5% CO2. HEK-293 cells growing in 25 cm2 flasks or six-
well plates containing 18 mm coverslips were used for western blot and fluorescence
imaging, respectively, were transiently transfected with the cDNA encoding the specified
proteins using TransFectin™ Lipid Reagent (Bio-Rad Laboratories, Hercules, CA, USA).
Membrane suspensions from transfected HEK cells were obtained as described previously
(Fernandez-Duenas et al., 2012).
2.5. Gel electrophoresis, immunoblotting and immunocytochemistry
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) was performed
using 7.5 % polyacrylamide gels. Proteins were transferred to PVDF membranes using a
semi-dry transfer system, immunoblotted with the indicated antibodies and then bands
detected using a chemiluminescent detection kit (Pierce). Immunocytochemistry
experiments were performed as previously described (Ciruela et al., 2006).
2.6. [3H]-cAMP assay
The accumulation of cAMP was measured with a [3H]-cAMP assay system (GE Healthcare,
Piscataway, NJ, USA). In brief, transiently transfected HEK-293 cells were grown O/N in
serum-free DMEM containing adenosine deaminase (0.5 U/mL), preincubated with 50 µM
of the phosphodiesterase inhibitor zardaverine for 10 min and then stimulated with
adenosine (10 µM) for 15 min at 37° C. Then, we performed the assay protocol, adding the
labelled [3H]-cAMP, as described in the manufacturer's manual. The radioactivity was
determined in scintillation vials using a Packard 1600 TRI-CARB scintillation counter
(PerkinElmer, Waltham, MA, USA).
2.7. Microscopic FRET measurements
Single-cell real-time FRET experiments with the MRS5424 ligand, in cells expressing the
A2ARCFP construct and the D2RAGT stained by means of the SNAP-Surface 647 ligand
(New England BioLabs, Ipswich, MA, USA), were performed as previously described
(Fernandez-Duenas et al., 2012).
2.8. Flow cytometry analysis
Transiently transfected HEK-293 cells were detached with accutase (Sigma-Aldrich) and
resuspended in Hank’s balanced salt solution containing 1 g/l glucose (HBSS). Then, cells
were incubated with the proper ligands in silicon-coated reaction vessels (3×105 cells/50 µl)
during 60 minutes at room temperature and used directly for flow cytometric measurements.
For each binding condition tested 104 cells were analyzed using a FACSCalibur™ flow
cytometer (Becton Dickinson, Heidelberg, Germany) with excitation at 488 nm and
emission at 510 nm. Samples were maintained in the dark during the analysis to avoid
photobleaching. Fluorescence intensities were obtained in the FL-1 channel in log mode.
Data were collected using Cell Quest Pro software (BD, Franklin Lakes, NJ) and analyzed
by GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
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The number of samples (n) in each experimental condition is indicated in figure legends.
Statistical analysis was performed by one-way ANOVA followed by Dunnett`s multiple
comparison post-hoc test. Statistical significance is indicated for each experiment.
3. Results and discussion
In the next years, the search for new drugs specifically targeting the A2AR/D2R complex
may represent a novel and therapeutically superior approach for the management of PD. In
such way, drugs intended to overcome the tonic A2AR-mediated inhibition of D2R signalling
promise to be of great value. Accordingly, in the present work we aimed to study the D2R-
mediated allosteric modulation of A2AR agonist binding within the A2AR/D2R oligomer
framework. Hence, we developed a FRET- and a flow cytometry-based agonist binding
assays devoted to study the adenosine-dopamine receptor-receptor interaction.
3.1. FRET determinations of D2R-mediated modulation of A2AR binding
We recently described a single-cell real-time FRET-based A2AR agonist binding procedure,
in which it was possible to ascertain the negative allosteric modulatory effect of a D2R
agonist (i.e. quinpirole) on A2AR agonist binding (Fernandez-Duenas et al., 2012).
Accordingly, here we aimed to use the same experimental approach to analyze the effects of
several clinically used antiparkinsonian drugs (i.e. pramipexole, rotigotine and
apomorphine) on A2AR agonist binding (Figure 1A). First, doubly A2ARCFP and D2RAGT
transfected cells were visualized at 480 nm (CFP) and 688 nm (SNAP; see methods).
Noteworthy, the A2ARCFP construct was, without losing its functionality, mostly targeted to
the plasma membrane (see Supplementary Figure 1), where it co-distributed with the
D2RAGT (Fernandez-Duenas et al., 2012). Then, we proceeded to analyze the effects of the
antiparkinsonian agents on MRS5424 binding. Since it has been previously demonstrated
that in real-time FRET determinations there is not receptor reserve and furthermore the
measurements are done under continuous superfusion of the ligand (i.e. non-equilibrium
conditions) (Ziegler et al., 2011), high saturating concentrations of the antiparkinsonian D2R
agonists (pramipexole: 120 µM, rotigotine: 1 µM and apomorphine: 6 µM) (Millan et al.,
2002,Scheller et al., 2009) were used to displace the MRS5424 (2 µM) bound to A2ARs.
Interestingly, while MRS5424 binding was unaffected by any of the D2R agonists in cells
expressing only the A2ARCFP (data not shown), upon D2RAGT co-expression and challenge
a significant lower FRET signal was observed (Figure 1B). A close view of the real-time
FRET profiles allowed us to discern that apomorphine (58±6%, p < 0.001) was the most
efficacious negative allosteric modulator (NAM) of A2AR agonist binding, when compared
to rotigotine (29±5%, p < 0.001) or pramipexole (38±5%, p < 0.001) (Figure 1C). Overall,
these results indicated that all D2R agonists tested were NAMs of A2AR agonist binding, a
phenomenon that would be dependent on A2AR/D2R oligomerization. Indeed, we recently
demonstrated that the formation of the A2AR/D2R oligomer was mandatory for the observed
receptor-receptor interaction (Fernandez-Duenas et al., 2012).
3.2. Flow cytometric measurements of D2R-agonists effects on A2AR binding
One of the main advantages of FRET-based approaches consists of providing high
spatiotemporal resolution of the agonist-receptor interaction. On the contrary, this kind of
tool does not permit the collection of a large number of events, therefore not suitable for
high throughput screening of drugs. Accordingly, in order to validate our previous results by
a different experimental approach and also to generate an easy, fast and reliable way for
monitoring A2AR-D2R interactions we aimed to develop a flow cytometry homogeneous no-
wash assay. First, a new selective A2AR fluorescent agonist, a pure isomeric APECAlexa488
named MRS5206, was synthesized according to our flow cytometer needs. First, it was
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tested to be bound selectively to the A2AR by live-cell detection under a fluorescence
microscope (see Supplementary Figure 2). And thereafter, we attempted to quantify the
occurrence of MRS5206 binding to A2ARs by means of flow cytometry. To this end, A2AR
expressing cells were initially incubated with MRS5206 and then separated by flow
cytometry with the aid of both forward and sideward scatter signals. Interestingly, while
MRS5206 did not bind to mock transfected cells (data not shown), a concentration-
dependent binding isotherm for A2AR expressing cells was found when positive cells or
events (Figure 2A, inset histogram) were plotted against MRS5206 concentration (Figure
2A). A close analysis of these results revealed that the maximal MRS5206 binding capacity
identified ~33% of positive cells, and this was achieved at low nanomolar concentrations of
MRS5206. This value may depend on the existing interrelation between cell surface receptor
density and transfection efficiency achieved in our experiments. On the other hand,
MRS5206 binding was completely blocked by ZM241,385 (1 µM) at any MRS5206
concentration tested, thus demonstrating the specificity of the fluorescent compound (Figure
2A). Also, we evaluated the affinity of MRS5206 by competitive ligand binding
experiments. Thus, a fixed dose of MRS5206 (100 nM) was displaced with CGS21680,
another A2AR selective agonist, in a concentration-dependent manner (Figure 2B). The
dissociation constant of CGS21680 (106±42 nM) was similar to that described in the
literature by means of radioligand experiments (Ciruela et al., 2006). Interestingly, these
results were consistent with previous observations of fluorescent ligand binding for other
GPCRs using flow cytometry under equilibrium conditions (Schneider et al., 2006). Thus,
we finally carried out flow cytometry binding experiments using the antiparkinsonian drugs.
Importantly, while in cells transfected only with the A2AR-containing plasmid the D2R
agonists did not alter MRS5206 binding to A2ARs (data not shown), in A2AR-D2R co-
expressing cells all the antiparkinsonian agents tested produced a significant reduction of
MRS5206 (100 nM) binding (Figure 2C), with apomorphine again achieving the largest
binding inhibition (42±7%, p < 0.01) in comparison to rotigotine (22±3%, p < 0.01) and
pramipexole (29±7%, p < 0.01) (Figure 2C).
4. Conclusion
The two different experimental approaches presented here permitted us to evaluate the
degree of D2R-mediated allosteric modulation of A2AR agonist binding within the A2AR/
D2R oligomer framework. Hence, it could be concluded that both our FRET- and flow
cytometry-based agonist binding assays would be valuable for determining the D2R agonist
NAM activity of different antiparkinsonian agents over A2AR functioning. Needless to say,
the relevance of this information for the design of effective D2R-based antiparkinsonian
therapies is intrinsically limited, since the experiments were performed in a heterologous
system. Thus, it is important to keep in mind that any new emerging D2R-based drug with
A2AR NAM activity should be first tested in PD animal models before attempting some
clinical extrapolation. And on the other hand, it would also be important to correlate the
degree of the discovered properties of apomorphine, rotigotine, and pramipexole with their
effectiveness as antiparkinsonian drugs. Overall, the present methods are mainly
circumscribed to the mechanistic elucidation of the receptor-receptor interaction occurring
between A2ARs and D2Rs, but they may also be viewed as possible complementary tools on
the development of D2R-like drugs targeted to the management of Parkinson’s disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Real-time FRET determinations of antiparkinsonian D2R agonist-mediated
modulation of A2AR agonist binding
(A) Chemical structures of the investigated antiparkinsonian D2R agonists (pramipexole,
rotigotine and apomorphine). (B) Time-resolved changes in FRET signals engaged by
MRS5424 (2 µM) in cells transfected with A2ARCFP and D2RAGT in the absence (black
trace) or presence (red trace) of pramipexole (120 µM), rotigotine (1 µM) and apomorphine
(6 µM) were recorded. Traces are representative of four separate experiments with similar
qualitative and quantitative results. (C) The FRET increase (1/F480) was fitted by a simple
monoexponential curve and the magnitude of the FRET signal (A, see experimental
procedures) calculated for each experimental condition. Data represents the average ±
S.E.M. values of four independent experiments. Asterisk indicates data significantly
different from the control condition (i.e. in the absence of antiparkinsonian D2R agonist): *p
< 0.01 by ANOVA with Dunnett`s multiple comparison post-hoc test.
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Figure 2. Flow cytometric determinations of antiparkinsonian D2R agonist-mediated modulation
of A2AR agonist binding
(A) The flow cytometric equilibrium binding assay. HEK-293 cells transiently transfected
with A2AR were incubated with increasing concentrations of MRS5206 and analyzed by
flow cytometry. In the inset panel a representative histogram of MRS5206 (100 nM) total
binding (black line) and nonspecific binding (red line, in the presence of 1 µM of
ZM241,385) is shown. The specific fluorescence detection (FL-1) for each MRS5206
concentration tested was determined by M1 cursor (see histogram). Thus, specific events
within the M1 region were plotted against MRS5206 concentration. (B) Competition
between MRS5206 (100 nM) and increasing concentrations of CGS21680, another specific
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A2AR agonist. The geometric fluorescence mean within the M1 region events was plotted
against each CGS21680 concentration tested. (C) Quantification of antiparkinsonian D2R
agonists effects on MRS5206 binding. HEK-293 cells transiently transfected with A2AR and
D2R were incubated with 100 nM of MRS5206 in the absence or presence of quinpirole
(100 µM), pramipexole (120 µM), rotigotine (1 µM) and apomorphine (6 µM) and analyzed
by flow cytometry. The obtained geometric fluorescence mean within the M1 region events
for each equilibrium binding condition was plotted. Data represents the average ± S.E.M.
values of three independent experiments. Asterisks indicate data significantly different from
the control condition (i.e. in the absence of antiparkinsonian D2R agonist): *p < 0.05 and
**p < 0.01 by ANOVA with Dunnett`s multiple comparison post-hoc test.
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